Loading…

Log in to bookmark your favorites and sync them to your phone or calendar.

Health [clear filter]
Tuesday, March 5
 

10:00am

European Research on Rare Diseases: Exploring Public Private Investment Synergies

Rare diseases affect close to 30 million people in the EU-27 and despite the high quality of public research and the existence of 'centres of excellence', there is a lack of innovative approaches for the development of new therapies. The definition of optimised methods and resources use requires coordination in both investments and infrastructures that only a Public Private Partnership approach can supply. The conference will explore how to leverage existing models to promote best practises in the field.

Speakers include researchers from rare disease centres in France, Italy, U.K. and Germany.


Speakers
VP

Vittorio Prodi, MEP

Chair of the Sky and Space Intergroup


Tuesday March 5, 2013 10:00am - 12:30pm
European Parliament A1G2

4:00pm

Global Health Challenges and Economic Implications
Limited Capacity seats available

The world has started facing a dramatic change in global health challenges. On top of the unmet needs to
combat communicable diseases especially in the developing world our societies become larger, older and unhealthier. We even export most of these life style diseases into the low and most prominently the medium income countries (LMIC). 2/3 of all new cancer cases in 2030 can be estimated to be diagnosed in LMIC, the highest increase in type 2 diabetes and glucose intolerance will be seen in LMICs. At the same time public health spending is increasing already and the need for an economic return for Pharma is becoming shorter. For big Innovations first stage funding is seen as too risky and seed funding instruments are unattractive for investors.

Healthcare systems have no proper solutions in place to cope with the upcoming health challenges and
countries have no strategy how to finance healthcare under these expected developments. This situation will result in a major threat for global economy. There is a need for new solutions for better prevention of diseases and more efficient cures. These solutions have to emerge from top level research requiring also new financing instruments to enable efficient translation of research into innovation.

 

Agenda

 


Moderators
avatar for Nessa Childers

Nessa Childers

Member of the European Parliament, European Parliament
Nessa Childers is an Irish Labour Party politician and Member of the European Parliament (MEP) for the Ireland East constituency.  Previously Nessa was a councillor for the Blackrock area of South Dublin 2004–2008. | A member of the European Parliament's Committee on the Environment... Read More →

Speakers
avatar for Peter Boyle

Peter Boyle

President of the International Prevention Research Institute, Lyon, France
Dr Boyle’s appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on his tenure as Director of the International Agency for Research on Cancer (IARC/WHO) from 2004 to 2008 in Lyon, France. He previously had had a number of successive... Read More →
avatar for David Byrne

David Byrne

David Byrne was appointed EU Commissioner in 1999 and held the portfolio of Health and Consumer Affairs during the Prodi Commission, when he established the European Centre for Disease Control (ECDC) and the European Food Safety Authority (EFSA). Prior to that, he served as Attorney... Read More →
avatar for Geoffrey Hamilton-Fairley

Geoffrey Hamilton-Fairley

Executive Chairman, Oncimmune Ltd
Geoffrey Hamilton-Fairley’s entrepreneurial career started in 1982 by founding a number of companies in the media sector backed by The Abingdon Management Company Limited (Abingdon) - an institutional venture capital company. In 1988 he joined the board of Abingdon as CEO and subsequently... Read More →
avatar for Barbara James

Barbara James

Founder and CEO of Henshaw Capital Partners
Barbara is founder and CEO of the first independent pan-African private equity Fund of Funds - Henshaw Capital Partners. | Barbara served on the Nigerian Federal Government Committee on Information Technology Incubation Centre Development in 2011/2012 and on the Nigerian Federal... Read More →
avatar for Martin Murphy

Martin Murphy

Chief Executive Officer of Syncona Partners LLP
Martin is the Chief Executive Officer of Syncona Partners LLP.  Previously, he was a Partner at MVM Life Science Partners LLP, a leading venture capital company focused on life science and healthcare investments. During his time at MVM, Martin was a member of the Management and Investment... Read More →
avatar for Andrea Ponti

Andrea Ponti

Managing Director, Co-Head of Global Healthcare
Andrea joined J.P. Morgan from Goldman Sachs where he was Partner Managing Director and Head of European Healthcare, Consumer and Retail based in London. In addition to founding the Goldman Sachs European Healthcare group in 1997, Andrea covered a variety of roles as Chief Operating... Read More →


Tuesday March 5, 2013 4:00pm - 6:00pm
European Parliament A3H1
 
Wednesday, March 6
 

9:30am

The Virtual Patient – The Future of Medicine
Limited Capacity seats available

As personalised medicine enters clinical and public health practice, its wider implementation requires favourable health policies and a new health infrastructure. Personalised Medicine is expected to allow our current, largely reactive mode of medicine to be replaced over the next years by a personalised, predictive, preventive, and participatory medicine. Europe has to provide citizens with access to emerging knowledge and technologies which will aid them in achieving a better quality of life over an extended lifetime. Information and Communication Technology (ICT) has been identified as one of the bottlenecks. Due to growing demands for data-rich, individualised medicine, ICT and healthcare are increasingly merging. As data-intensive analysis and computer-intensive modelling become common practice, this will result in a shift from personnel-intensive to ICT-intensive applications. Modelling will be used to generate “Virtual Patients”, such that each citizen might conceivably have a “virtual twin” that can be used to simulate and predict outcomes such as response to therapeutic or preventive interventions. To accelerate the development of personalised medicine, personal health and individualised healthcare global collaborations of researchers in academia, industry, SMEs, patient groups and regulatory authorities are needed, preferably as public-private partnerships, to ensure that research results are translated into tangible benefits for citizens.

 

Agenda

 


Moderators
avatar for Helmut Brand

Helmut Brand

Professor European Public Health, Department of International Health at Maastricht University
Helmut Brand is a Jean Monnet Professor of European Public Health and Head of the Department of International Health at Maastricht University. He has developed a successful career combining competencies related to practice in the area of public health and management at the level... Read More →
avatar for Hans Lehrach

Hans Lehrach

Hans Lehrach obtained his Ph.D. at the Max Planck Institute for Experimental Medicine and the Max Planck Institute for Biophysical Chemistry in 1974. Next he moved on to Harvard University, Boston (1974-1978) for a postdoc and then became group leader at EMBL, Heidelberg (1978-1987... Read More →

Speakers
avatar for Peter Boyle

Peter Boyle

President of the International Prevention Research Institute, Lyon, France
Dr Boyle’s appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on his tenure as Director of the International Agency for Research on Cancer (IARC/WHO) from 2004 to 2008 in Lyon, France. He previously had had a number of successive... Read More →
avatar for Angela Brand

Angela Brand

Institute for Public Health Genomics, Maastricht University, The Netherlands
Presentation topic: Personalised Healthcare – what and how to translate?   Prof. Angela Brand, MD PhD MPH (USA) is Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG) at the Faculty of Health, Medicine and Life Sciences at Maastricht University... Read More →
avatar for David Byrne

David Byrne

David Byrne was appointed EU Commissioner in 1999 and held the portfolio of Health and Consumer Affairs during the Prodi Commission, when he established the European Centre for Disease Control (ECDC) and the European Food Safety Authority (EFSA). Prior to that, he served as Attorney... Read More →
avatar for Morten Ernebjerg

Morten Ernebjerg

Developer at the SAP Innovation Center Potsdam
Morten Ernebjerg got his PhD in theoretical physics from Harvard University in 2007. Fascinated by the use of modeling in biology, he then became a Postdoctoral Fellow at the Department of Systems Biology at Harvard Medical School. During his five years there, he worked on the ecology... Read More →
avatar for Magda Gunn

Magda Gunn

Scientific Manager at IMI
Magda Gunn has obtained her master’s degree in chemistry from Adam Mickiewicz University in Poznan, Poland in 2001. In 2007 she obtained her Ph.D. in chemistry from North Carolina State University in Raleigh, North Carolina, USA. | Her career continued at a biotech company SomaLogic... Read More →
avatar for Ivo Gut

Ivo Gut

Director Centre Nacional d'Anàlisi Genòmica (CNAG)
Ivo Gut is qualified in Chemistry at the University of Basel and obtained a PhD in Physical Chemistry from the same University with Prof. Jakob Wirz in 1990.  He was a Research Fellow in the group of Prof. Irene Kochevar at Harvard Medical School (1990-1993), and in the laboratory... Read More →
avatar for Walter Kolch

Walter Kolch

Director of Systems Biology Ireland
Prior to his appointment as SBI Director, Professor Walter Kolch was a Senior Group Leader at the Beatson Institute for Cancer Research, and Professor for Molecular Cell Biology at the University of Glasgow, Scotland. Walter is also Director of the UCD Conway Institute, an interdisciplinary... Read More →
avatar for Hans Lehrach

Hans Lehrach

Hans Lehrach obtained his Ph.D. at the Max Planck Institute for Experimental Medicine and the Max Planck Institute for Biophysical Chemistry in 1974. Next he moved on to Harvard University, Boston (1974-1978) for a postdoc and then became group leader at EMBL, Heidelberg (1978-1987... Read More →
avatar for Kurt Zatloukal

Kurt Zatloukal

Professor of Pathology at the Medical University of Graz, Austria
Kurt Zatloukal, M.D. is professor of Pathology at the Medical University of Graz, Austria. He coordinated the preparatory phase of the European biobanking and biomolecular research infrastructure (BBMRI-ERIC) within the 7th EU framework programme. In this context it was crucial to... Read More →


Wednesday March 6, 2013 9:30am - 12:30pm
European Parliament P5B001

2:00pm

Biobanks: Key-Resources for the Advancement of Biotechnology and Human Health
Limited Capacity seats available

Revealing the molecular basis of diseases will depend critically on the availability of well-documented, high quality biological samples from large numbers of patients and healthy persons, collected and made available by biobanks. Human biological samples, including associated medical and molecular data are key resources in unraveling genetic and environmental factors causing diseases and influencing their outcome. These resources are required for development of new solutions to improve prevention, diagnosis and treatment of diseases.

The pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-ERIC) will further develop and provide access to these key resources in a quality controlled and ethically and legally compliant manner. Although BBMRI-ERIC is a European initiative much emphasis is placed on global cooperation and the development of globally harmonized biobanking-related processes and standards.
BBMRI-ERIC builds on OECD guidelines pertinent to biobanking and should become the European part of global biological resource centres network (GBRCN) as specified by OECD.

This seminar will present BBMRI-ERIC as well as several other leading biobanking initiatives in Europe and outside of Europe. Key measures to improve international collaboration and interoperability of biobanks will be discussed.

 

Agenda

 


Moderators
avatar for Jennifer Harris

Jennifer Harris

Senior Researcher at the Norwegian Institute of Public Health, The Norwegian Institute of Public Health
Dr. Jennifer Harris is a Senior Researcher at the Norwegian Institute of Public Health in Oslo Norway where she leads the program in genetic epidemiology. She has interdisciplinary training in life-span development, genetics, behavior and epidemiology. Since 2000 she has also been... Read More →

Speakers
avatar for Anne Cambon-Thomsen

Anne Cambon-Thomsen

Director of Research in CNRS (French national centre for scientific research)
Anne Cambon-Thomsen, MD, is Director of Research in CNRS (French national centre for scientific research) working in a research Unit on epidemiology and public health at Inserm (National Institute for Health and Medical Research), and University of Toulouse III Paul Sabatier, Faculty... Read More →
avatar for Georges Dagher

Georges Dagher

Research director, INSERM
Georges Dagher, senior investigator at Inserm (Paris, France) accomplished most of his career in pathophysiological and clinical research at Necker Hospital (1979-1984), College de France (1985-1993) and Faculty of medicine Broussais-Hotel Dieu (1994-2004). He joined the Physiological... Read More →
avatar for Monica Ensini

Monica Ensini

Scientific Direcotr EURORDIS
Monica Ensini holds a PhD in Neurobiology obtained from the University of Pisa and Scuola Normale Superiore of Pisa, Italy. During her postdoctoral training at Columbia University (New York, USA) she focused her research studies on the development of the vertebrate motor system. Subsequently... Read More →
avatar for Isabel Fortier

Isabel Fortier

Director of Research and Development P3G Consortium
Dr Isabel Fortier is researcher at the Research Institute of the McGill University Health Centre where she leads the Maelstrom Research and DataSHaPER programs. These initiatives aim to develop and provide the research community from diverse disciplines with resources (expertise... Read More →
avatar for Peadar Mac Gabhann

Peadar Mac Gabhann

Director, Biostór Ireland
In the last 5 years Peadar has founded & developed two Life Science companies. Biostór, Ireland’s first independent Tissue Establishment, licensed by the Irish Medicines Board under the EU Tissue & Cells Directives & provides certified storage & distribution services to hospitals/clinics... Read More →
avatar for Rongxing Gan

Rongxing Gan

Director of Shanghai Clinical Research Center
Dr. Rongxing Gan, Director of Shanghai Clinical Research Center (SCRC), has more than 20 years’ experience in research and development in biotechnology and pharmaceuticals, technology transfer, business development and venture capital. He has been the vice president of the leading... Read More →
MH

Marianne Henderson

Former ISBER President
avatar for Bartha Maria Knoppers

Bartha Maria Knoppers

Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University
Bartha Maria Knoppers, PhD (Comparative Medical Law), holds the Canada Research Chair in Law and Medicine (Tier 1: 2001 - ). She is Director of the Centre of Genomics and Policy, Faculty of Medicine, Department of Human Genetics, McGill University.  In 2007, she founded the international... Read More →
avatar for Rita Lawlor

Rita Lawlor

President ESBB, European, Middle Eastern and African Society of Biopreservation and Biobanking, European, Middle Eastern and African Society of Biopreservation and Biobanking
Rita Lawlor is president of ESBB, the European, Middle Eastern and African Society for Biopreservation and Biobanking, www.esbb.org. She is founder and the project manager of the ARC-NET (www.arc-net.it) cancer research centre at the University of Verona, Italy. She project manag... Read More →
avatar for Markus Perola

Markus Perola

Coordinator BBMRI-LPC
Dr. Perola is leading the Quantitative Genetics-group in the Public Health Genomics Unit, at the National Institute of Health and Welfare, Finland and a visiting professor in University of Tartu, Estonian Genome Project, Estonia. His studies have from been focusing on the genetics... Read More →
avatar for Ronald Stolk

Ronald Stolk

www.EpidemiologyGroningen.nl
See www.rug.nl/research/epidemiology/stolk
avatar for Kurt Zatloukal

Kurt Zatloukal

Professor of Pathology at the Medical University of Graz, Austria
Kurt Zatloukal, M.D. is professor of Pathology at the Medical University of Graz, Austria. He coordinated the preparatory phase of the European biobanking and biomolecular research infrastructure (BBMRI-ERIC) within the 7th EU framework programme. In this context it was crucial to... Read More →


Wednesday March 6, 2013 2:00pm - 4:00pm
European Parliament A3F383

6:00pm

Promoting Excellence in R&D for Global Health
Limited Capacity seats available

PREFERENCE IS GIVEN TO PEOPLE WHO RECEIVED SPECIFIC INVITATIONS FOR THIS SEMINAR

 

The goal of this session is to showcase successful avenues for excellence in research and development for Global Health, with a particular focus on the benefits of international and cross-sectorial cooperation. While negotiations on Horizon 2020 continue, financing for research and development for Global Health will be addressed primarily by the EDCTP, but also ERC and possibly IMI. We would look at how these instruments are generating opportunities to expand and accelerate R&D for PRNDs by rewarding scientific excellence and fostering the collaboration between partners with distinct areas of expertise and capacities.


Moderators
avatar for Maria Da Graça Carvalho

Maria Da Graça Carvalho

Member of the European Parliament
Maria da Graça Carvalho is a member of the European Parliament in the PPE group since 14 July 2009 (member of the ITRE-Industry, Research and Energy Committee, substitute member of the Budgets Committee and member of the ACP-UE Joint Parliamentary Assembly). She was elected co- President... Read More →
avatar for Karen Hoehn

Karen Hoehn

Vice Executive Director and Director of International Affairs, DSW, Deutsche Stiftung Weltbevölkerung
Karen Hoehn, Vice Executive Director and Director of International Affairs working with the German Foundation for World Population (DSW) since 2005, has 25 years experience influencing public policy and leveraging resources. Based first in Washington, DC and then Brussels, Belgium... Read More →

Speakers
avatar for Theodore Papazoglou, Ph.D.,

Theodore Papazoglou, Ph.D.,

Head of Unit, Support to the European Research Council Scientific Council, ERC Executive Agency
Theodore G. Papazoglou graduated with honors from the Physics Department of the University of Crete, Greece in 1985 and followed his graduate studies at the University of Southern California (PhD in Biomedical Engineering in 1990). After his post-doctoral training at the Cedars Sinai... Read More →
avatar for Sally Ethelston

Sally Ethelston

Director, Communications and Advocacy PATH Malaria Vaccine Initiative (MVI)
Sally Ethelston is Director, Communications and Advocacy with the PATH Malaria Vaccine Initiative (MVI). MVI was established as a program of PATH in 1999, to accelerate the development of malaria vaccines and catalyze timely access in endemic countries. MVI's vision is a world free... Read More →
avatar for Prof Bruno Gryseels

Prof Bruno Gryseels

Director of the Institute of Tropical Medicine (ITM) at Antwerp
Bruno M.A.J. Gryseels studied medicine at the State University of Ghent (1972-1979), and Tropical Medicine and Hygiene at the ITM in Antwerp (1979). He obtained his PhD at the University of Leiden (NL) in 1990. | After his studies he joined the ITM as a researcher in the Department... Read More →
avatar for Dr. Line Matthiessen

Dr. Line Matthiessen

Head of Unit - Infectious Diseases and Public Health, DG Research & Innovation, European Commission
Dr. Line Matthiessen leads the Unit responsible for Infectious Diseases and Public Health in the Directorate-General for Research and Innovation. The Unit promotes and supports EU research and innovation activities in the area of global health issues with emphasis on HIV/AIDS, malaria... Read More →
avatar for Dr Fil Randazzo

Dr Fil Randazzo

Deputy Director Global Health Discovery and Translational Science, Bill and Melinda Gates Foundation
Fil Randazzo currently serves as Deputy Director of Global Heath Discovery and Translational Sciences at the Bill & Melinda Gates Foundation where he is charged with managing a broad array of programs. Mr. Randazzo has recently been leading the development of the Vaccine Discovery... Read More →
avatar for Ms Elisabetta Vaudano

Ms Elisabetta Vaudano

Principal Scientific Manager, Innovative Medicines Initiative
Italian born Elisabetta Vaudano works as coordinator of the Scientific Pillar at the Innovative Medicines Initiative (IMI), the largest Public Private partnership in Health Sciences with a total budget of 2 billion EUR. Ms. Vaudano is a doctor in veterinary medicine and has a PhD... Read More →


Wednesday March 6, 2013 6:00pm - 8:00pm
European Parliament A3F383
 
Thursday, March 7
 

9:00am

Global Challenges and Global Collaboration in Assistive Technologies
Limited Capacity seats available

The Assistive Technologies Events at ES:GC2  will engage participants in discussing new strategies and global opportunities for influencing disability research that will benefit individuals with autism and intellectual disabilities in developed countries and low-resourced communities. The presentations will highlight the potential for positive global impact that is envisioned by the DOCTRID International Research Institute and its international partners in the EU, USA, Canada and Japan.


Three key areas will be explored in the course of the Symposium and Workshop:

1. Establishing and utilizing internationally-based collaborations to conduct Assistive Technology research using EU Horizon 2020 Funding instruments.

2. Creating a global Assistive Technologies consortium that will access and utilize new European Union research and development funding to partner in collaborative research.

3. Maximizing the role of international Assistive Technologies R&D structures including DOCTRID and AAATE, the private sector, advocacy groups and charities that can expand access to diverse networks, assess research initiatives for broader impact and advise on policy and new directions.

 

Activities
 
Meeting: Early-bird AT Workshop for Speakers (by invitation only)
Date: Tuesday 5th March
Time: 9.30am-1.00pm
Venue: Enterprise Ireland Office Brussels 
 
Meeting: AT Symposium Speakers pre-symposium Workshop (by invitation only)
Date: Wednesday 6th March
Time: 2.00pm-4.00pm
Venue: ISC Offices

Meeting: AT Symposium (open to people registered to the Conference)
Date: Thursday 7th March
Time: 9.00am-12.00pm
Venue: EU Parliament
 
Meeting: AT Workshop (open to all)
Date: Thursday 7th March
Time: 2.00pm-6.00pm
Venue: Radisson BLU EU Hotel – Schuman Meeting Room

 

Agenda

 


Moderators
avatar for Prof. Ian Gray

Prof. Ian Gray

Symposium Co-Chair
Ian Gray currently develops interdisciplinary research initiatives for Michigan State University in global food safety and security, food processing, and autism and intellectual disabilities. A native of Northern Ireland, Ian received his doctoral degree from Queen’s University... Read More →
avatar for Prof. Brian Harvey

Prof. Brian Harvey

Director of Research, DOCTRID International Programme in Research and Technology for Intellectual Disability
Brian Harvey was the first and longest-serving Vice-President for Research appointed in an Irish University from 1998-2010. Through this role, he co-ordinated large-scale national and EU research programmes bringing in over €300million in funding which has contributed to the building... Read More →
avatar for Lynnae Ruttledge

Lynnae Ruttledge

International disability rights policy advisor, DOCTRID
Lynnae M. Ruttledge is a member of the US National Council on Disability, appointed by President Obama in 2013. In addition, she serves as a disability policy advisor to the international research institute, DOCTRID. Ms. Ruttledge served as Commissioner of the US Rehabilitation Services... Read More →

Speakers
avatar for Alixe Bonardi

Alixe Bonardi

Director, Center for Developmental Disabilities Evaluation and Research (CDDER)
Presentation Title: Assistive Technology Programs at the UMMS Shriver Center: An Overview and Perspectives Summary: Ms. Bonardi will provide a brief overview of programs at the Shriver Center of the University of Massachusetts Medical School that bear on assistive technology development... Read More →
avatar for Dr. Peter Cudd

Dr. Peter Cudd

Member of the board, Association for the Advancement for Assistive Technology in Europe (AAATE)
Peter Cudd BSc PhD is a Senior Research Associate in the School of Health and Related Research at the University of Sheffield, UK. He is a Member of the Board, Treasurer, and the UK national contact person of the Association for the Advancement of Assistive Technology in Europe. Starting... Read More →
avatar for Dr. Mick Donegan

Dr. Mick Donegan

Associate Senior Research Fellow, University College, Dublin; CEO & Founder ‘SpecialEffect’
Dr. Mick Donegan, Adjunct Professor, Faculty of Design, OCAD University, Toronto. Associate Senior Research Fellow, University College, Dublin, CEO & Founder ‘SpecialEffect’, a UK-based Assistive Technology Charity www.specialeffect.org.uk which uses specialised technology to enhance access to videogames and creative self-expression for people with a wide range of disabilities.  Mick’s research draws on his many years of practice-based work as a teacher and an Assistive Technology specialist who has extensive experience in assessing, teaching, training, and supporting peop... Read More →
avatar for Takenobu Inoue

Takenobu Inoue

Director, Department of Assistive Technology, Research Institute
Takenobu Inoue, MSE, Director, Department of Assistive Technology, Research Institute, The National Rehabilitation Center for Persons with Disabilities, Japan. Advisor, RESJA (Rehabilitation Engineering Society of Japan).Takenobu Inoue carries out research related to assistive technology... Read More →
avatar for Cian O’Mathuna

Cian O’Mathuna

Head of Microsystems Centre, Tyndall National Institute, UCC Ireland
Prof. Ó Mathúna is Head of the Microsystems Centre at the Tyndall National Institute in Cork, Ireland. With a compliment of over 80 researchers, led by 12 Principal Investigators and an annual budget of €5M, the Centre incorporates two Research Groups - Microelectronics Applications... Read More →
avatar for Mark Harniss, Ph.D.

Mark Harniss, Ph.D.

Clinical Associate Professor, Department of Rehabilitation Medicine, University of Washington
Presentation Title: Cognitive Support Technologies across Resource Settings Summary: This presentation describes the development of cognitive support technologies (based on sensor technology, activity recognition, and machine-based learning) designed for implementation in high-resourced... Read More →
avatar for Prof. Paul Whelan

Prof. Paul Whelan

Professor of Computer Vision, Director of Centre for Image Processing & Analysis, Dublin City University, Ireland
Prof Paul Whelan, Professor of Computer Vision, Director of Centre for Image Processing & Analysis, Dublin City University, Ireland. Prof. Paul F Whelan his Ph.D. (Computer Vision) from the Cardiff University (UK). During the period 1985-1990 he was employed by Industrial and Scientific... Read More →


Thursday March 7, 2013 9:00am - 12:00pm
European Parliament P5B001

10:00am

Worldwide Implementation of the 3Rs in Regulatory Toxicology - What are the Leadership Challenges and Opportunities?

This seminar will examine the state of alternatives to animal testing, the implementation of the 3Rs - Replacement, Refinement and Reduction – worldwide.

The EU member states have a long tradition of incorporating the 3Rs (replacement, reduction and refinement) into laws and policies. The tradition has extended to the organic documents that underlie the European Union (i.e., Article 13 of the Lisbon Treaty on the Functioning of the European Union). For example, EU’s chemical regulation (REACH), the Directive on the Protection of Animals Used for Scientific Purposes (2010/63/EU), and Cosmetics Regulation incorporate animal welfare into their basic policy schemes.

As in vitro, computational and other non-animal based approaches in toxicology have evolved, more and more nations have begun to incorporate 3Rs principles into their national laws and regulatory schemes.

This workshop will examine the state of the implementation of the 3Rs worldwide, with a focus on EU leadership and how the EU can continue its forward-looking approach to the 3Rs. The workshop will also assist in identifying ways to ensure high quality science and global consistency through opportunities for harmonization.

 

Agenda

 


Moderators
avatar for Joyce Tischler

Joyce Tischler

General Counsel at the Animal Legal Defense Fund
As one of the co-founders of the Animal Legal Defense Fund in 1979, California attorney Joyce Tischler has helped shape the emerging field of animal law. Joyce handled some of Animal Legal Defense Fund's earliest cases, including a 1981 lawsuit that halted the U.S. Navy's plan to... Read More →

Speakers
avatar for Mr. Richard Fosse

Mr. Richard Fosse

Vice President LAS World Wide at GlaxoSmithKline
Born and grew up in South Africa where he did his BVsc at the Faculty of Veterinary Medicine, Onderstepoort, University of Pretoria. Emigrated to Norway in 1972 where he did a PhD in Physiology and Endocrinology, specialising in hormone regulation of mineral metabolism at the Royal... Read More →
BH

Björn Hansen

Head of the Chemicals, Biocides and Nanomaterials Unit at DG Environment
Bjorn Hansen obtained his Masters degree from the State University of New York at Stony Brook, New York, U.S.A. in 1985 and his Ph.D. in 1988 from the Technical University in Eindhoven, the Netherlands. After a “habilitation post” at the Geog August University in Göttingen... Read More →
avatar for Brett Lidbury

Brett Lidbury

Associate Professor of Alternatives to Animal Research at The Australian National University
Brett Lidbury is a Science Honours graduate from the University of Newcastle and completed his Ph.D. (Immunobiology) at The Australian National University (ANU) in 1993. Since graduation he has conducted research at other Australian universities and in the United States, primarily... Read More →
avatar for Paul Locke

Paul Locke

Associate Professor at the Johns Hopkins University Bloomberg School of Public Health
Paul Locke, an environmental health scientist and attorney, is an Associate Professor at the Johns Hopkins University Bloomberg School of Public Health in the Department of Environmental Health Sciences, Division of Toxicology. He holds an MPH from Yale University School of Medicine... Read More →
avatar for Octavio Presgrave

Octavio Presgrave

National Institute of Quality Control in Health, Brazil, BraCVAM
Octavio Augusto França Presgrave is graduated in Biology (Universidade Gama Filho, Rio de Janeiro, Brazil, 1986) and works at the National Institute of Quality Control in Health (INCQS), an Official Laboratory of the Brazilian Ministery of Health, since 1982. Octavio has already... Read More →


Thursday March 7, 2013 10:00am - 12:00pm
European Parliament A4F384

1:00pm

New Regulatory Science in System Toxicology - Part I: Is an Update Needed, What Would Be the Critical Elements and by When?
Limited Capacity seats available

New regulatory science in system toxicology: is an update needed, what would be the critical elements and by when?

Regulatory toxicology is used to control about $10 trillion (£6.2 trillion) worth of worldwide trade in chemicals, drugs, pesticides, food and consumer products.

While Europe has been pursuing change under the label of alternative methods and the 3Rs (reduce, replace, refine) for more than two decades, it was only a 2007 National Research Council report on the subject that prompted serious efforts to change the US system. The 3Rs approach had suggested either optimising animal tests (fewer animals or less pain and distress) or replacing traditional tests with in vitro or in silico models for harmonization.

The answer emerging in Europe is to combine various information sources in integrated (or intelligent) testing strategies (ITS). Despite the enormous possible impact this could have with EU legislations like REACH or the testing ban for cosmetic ingredients, efforts to further this are still limited. The answer emerging in the US is to adopt a new, molecular description of toxic action based on pathways of toxicity (PoT) – the biomolecular pathways that lead to a cell being harmed. This approach represents a paradigm shift in toxicity testing – identifying a substances effect on harmful cellular pathways, rather than interpreting effects on cell lines or entire organisms.

Synergies exist between these two approaches and two economic partners. Joint efforts to keep
leadership and achieve results are seek.

 

Agenda

 


Moderators
avatar for Mr. Francois Busquet

Mr. Francois Busquet

Europe Policy Coordinator at Center for Alternatives to Animal Testing (CAAT)
François Busquet studied Biotechnologies at the ENSTBB in France. He graduated from the TU Dresden, completing his PhD at the MerckSerono group in Germany on the development of a new screening assay to detect proteratogenic compounds using zebrafish embryos. After his studies, he... Read More →

Speakers
avatar for Dr. Robert Barouki

Dr. Robert Barouki

Professor at the University Paris Descartes
Robert Barouki is a biochemist and molecular biologist whose main focus during the last fifteen years has been understanding the mechanisms of toxicity of environmental pollutants such as dioxin. In particular, he has studied the biological consequences following the activation of... Read More →
avatar for Dara Corrigan

Dara Corrigan

FDA Europe Office Director, FDA
Dara Corrigan heads the FDA’s Europe Office, located in Brussels. Ms. Corrigan serves as the FDA’s chief representative to the European Union (EU), working directly with the European Commission, European Medicines Agency and European Food Safety Agency. She also serves as liaison... Read More →
avatar for Rex Fitzgerald

Rex Fitzgerald

Regulatory toxicology expert at Swiss Centre For Applied Human Toxicology
"Rex FitzGerald graduated in zoology from Trinity College (Dublin, Ireland) and received a D.Phil in Biological Sciences at Sussex University (UK). He became a Diplomate of the American Board of Toxicology (DABT) in 1990 and was Head of Reproductive Toxicology at Ciba-Geigy, Stein... Read More →
avatar for Thomas Hartung

Thomas Hartung

CAAT US Director
Thomas Hartung, MD PhD, is professor and chair for toxicology, pharmacology, molecular microbiology, Evidence-based Toxicology and immunology at Johns Hopkins Bloomberg School of Public Health, Baltimore MD, and University of Konstanz, Germany. He directs the Centers of Alternative... Read More →
avatar for Adriano Henney

Adriano Henney

Programme Director German Virtual Liver Network
Dr Henney obtained a PhD in Medicine and has 23 years’ research experience in cardiovascular disease in laboratories in London, Cambridge and Oxford. His interests have focused predominantly on atherosclerosis, with studies ranging from pathology, through molecular and cellular... Read More →
avatar for Ms. Emily McIvor

Ms. Emily McIvor

Senior Policy Adviser for Humane Society International/Europe
Emily McIvor has worked on animal welfare issues at European Union level for many years, specialising in those concerning the use of animals in research and testing. As one of the lead animal welfare lobbyists in political negotiations of the EU Cosmetics Directive 7th Amendment... Read More →
VP

Vittorio Prodi, MEP

Chair of the Sky and Space Intergroup


Thursday March 7, 2013 1:00pm - 3:00pm
European Parliament A3H1

1:00pm

New Regulatory Science in System Toxicology - Part II: Is an Update Needed, What Would Be the Critical Elements and By When?
Limited Capacity seats available

New regulatory science in system toxicology: is an update needed, what would be the critical elements and by when?

Regulatory toxicology is used to control about $10 trillion (£6.2 trillion) worth of worldwide trade in chemicals, drugs, pesticides, food and consumer products.

While Europe has been pursuing change under the label of alternative methods and the 3Rs (reduce, replace, refine) for more than two decades, it was only a 2007 National Research Council report on the subject that prompted serious efforts to change the US system. The 3Rs approach had suggested either optimising animal tests (fewer animals or less pain and distress) or replacing traditional tests with in vitro or in silico models for harmonization.

The answer emerging in Europe is to combine various information sources in integrated (or intelligent) testing strategies (ITS). Despite the enormous possible impact this could have with EU legislations like REACH or the testing ban for cosmetic ingredients, efforts to further this are still limited. The answer emerging in the US is to adopt a new, molecular description of toxic action based on pathways of toxicity (PoT) – the biomolecular pathways that lead to a cell being harmed. This approach represents a paradigm shift in toxicity testing – identifying a substances effect on harmful cellular pathways, rather than interpreting effects on cell lines or entire organisms.

Synergies exist between these two approaches and two economic partners. Joint efforts to keep
leadership and achieve results are seek.



Agenda

 


Moderators
avatar for David Demortain

David Demortain

Political scientist with Sciences en Société (SenS)
David Demortain is a political scientist with the SENS (Sciences-en-Société) centre of the French Institut National de Recherche Agronomique (INRA), and a research associate of the Centre for Analysis of Risk and Regulation of the London School of Economics. His research and teaching... Read More →

Speakers
avatar for Bas Blaauboer

Bas Blaauboer

Doerenkamp-Zbinden Chair on Toxicology at IRAS-UU
Bas Blaauboer (1949) studied biology at Utrecht University and did a PhD in toxicology at the same university (1978). He spent a postdoctoral year at the MRC Toxicology Unit in the UK (1979), and when he returned to Utrecht led a group on in vitro toxicology (biochemical and cellular... Read More →
BD

Bob Diderich

Head of Division, Environment Directorate OECD, OECD
Bob Diderich has been involved in environmental hazard and risk assessment of chemical substances since 1992, when he joined the German Federal Environmental Agency. He was working in France between 1995 and 2002, first for the French Ministry of the Environment and then the French... Read More →
avatar for Thomas Hartung

Thomas Hartung

CAAT US Director
Thomas Hartung, MD PhD, is professor and chair for toxicology, pharmacology, molecular microbiology, Evidence-based Toxicology and immunology at Johns Hopkins Bloomberg School of Public Health, Baltimore MD, and University of Konstanz, Germany. He directs the Centers of Alternative... Read More →
avatar for Adriano Henney

Adriano Henney

Programme Director German Virtual Liver Network
Dr Henney obtained a PhD in Medicine and has 23 years’ research experience in cardiovascular disease in laboratories in London, Cambridge and Oxford. His interests have focused predominantly on atherosclerosis, with studies ranging from pathology, through molecular and cellular... Read More →
avatar for Bruno Hubesch

Bruno Hubesch

Dr Bruno Hubesch obtained his Master degree in Nuclear Chemistry in 1980 and his PhD in Physical Chemistry in the area of Photochemistry in 1985 from the University of Louvain, Belgium. During his PhD he carried out his research at the University of Strasbourg under supervision of... Read More →
avatar for Peter Lord

Peter Lord

Director, DiscoTox Ltd
I have spent a long career in cell and molecular toxicology, directing laboratories in the PreClinical Development Departments of several global Pharmaceutical Companies. I have championed the use of toxicogenomics in drug safety profiling and implemented cell and molecular biology... Read More →
VP

Vittorio Prodi, MEP

Chair of the Sky and Space Intergroup


Thursday March 7, 2013 1:00pm - 3:00pm
European Parliament A3H1

2:00pm

Workshop: People-centered assistive technologies & inclusive design
Limited Capacity seats available

The Assistive Technologies Events at ES:GC2  will engage participants in discussing new strategies and global opportunities for influencing disability research that will benefit individuals with autism and intellectual disabilities in developed countries and low-resourced communities. The presentations will highlight the potential for positive global impact that is envisioned by the DOCTRID International Research Institute and its international partners in the EU, USA, Canada and Japan.

Three key areas will be explored in the course of the Symposium and Workshop:
 
1. Establishing and utilizing internationally-based collaborations to conduct Assistive Technology research using EU Horizon 2020 Funding instruments.
 
2. Creating a global Assistive Technologies consortium that will access and utilize new European Union research and development funding to partner in collaborative research.
 
3. Maximizing the role of international Assistive Technologies R&D structures including DOCTRID and AAATE, the private sector, advocacy groups and charities that can expand access to diverse networks, assess research initiatives for broader impact and advise on policy and new directions.
 
 
 
Activities
 
Meeting: Early-bird AT Workshop for Speakers (by invitation only)
Date: Tuesday 5th March
Time: 9.30am-1.00pm
Venue: Enterprise Ireland Office Brussels 
 
Meeting: AT Symposium Speakers pre-symposium Workshop (by invitation only)
Date: Wednesday 6th March
Time: 2.00pm-4.00pm
Venue: ISC Offices
 
Meeting: AT Symposium (open to people registered to the Conference)
Date: Thursday 7th March
Time: 9.00am-12.00pm
Venue: EU Parliament
 
Meeting: AT Workshop (open to all)
Date: Thursday 7th March
Time: 2.00pm-6.00pm
Venue: Radisson BLU EU Hotel – Schuman Meeting Room 

 

Agenda

 


Moderators
avatar for Lynnae Ruttledge

Lynnae Ruttledge

International disability rights policy advisor, DOCTRID
Lynnae M. Ruttledge is a member of the US National Council on Disability, appointed by President Obama in 2013. In addition, she serves as a disability policy advisor to the international research institute, DOCTRID. Ms. Ruttledge served as Commissioner of the US Rehabilitation Services... Read More →

Speakers
avatar for Prof. Karola Dillenburger

Prof. Karola Dillenburger

Centre for Behaviour Analysis, Queen’s University Belfast, Northern Ireland
Prof Karola Dillenburger has worked extensively in social care and therapeutic settings in Germany before moving to Northern Ireland. She is the Director of the Centre for Behaviour Analysis in the School of Education at QUB. She has published widely, including 5 books, 5 multimedia... Read More →
avatar for Dr. John Dinsmore

Dr. John Dinsmore

Health Innovation Lead, Centre for Practice and Healthcare Innovation, Trinity College Dublin, Ireland
John Dinsmore is a health psychology researcher who’s work has focused on analysing behavioural change, illness perceptions, cognitive mediators, quality of life and quality of care of individuals living with chronic illnesses (including stroke, COPD, schizophrenia, dementia and... Read More →
avatar for Mark Dyer

Mark Dyer

Director Trinity Haus, School of Engineering, Trinity College Dublin, Ireland
Mark Dyer holds the Michael McNamara Chair in Construction Innovation at Trinity College Dublin since 2008 and is the founding director of the TrinityHaus research centre for sustainability and innovation in the built environment.  Previously he was Professor of Civil Engineering... Read More →
avatar for Prof. Lizbeth Goodman

Prof. Lizbeth Goodman

Director, SMARTlab and Chair of Creative Technology Innovation, University College Dublin
Lizbeth Goodman is Chair of Creative Technology Innovation and Professor of Inclusive Design for Education at University College Dublin, and an Executive Board member of the Innovation Academy (TCD, UCD, QUB), for which she runs the Social Entrepreneurship module and part of the core... Read More →
avatar for Gerardo Herrera

Gerardo Herrera

Director, Assistive Technology lab for autism, Robotics Institute, University of Valencia, Spain
Gerardo Herrera, MSc, is the responsible of the Autism & IT Group at the IRTIC Technological Institute.  He has a Degree in Computer Science from the University of Valladolid and holds a Master Degree in Computer Science from the University of Valencia. He founded the Autism Group... Read More →
avatar for Magí Almirall Hill

Magí Almirall Hill

Director, Office of Learning Technologies, Open University of Catalonia, Barcelona, Spain
Magí Almirall works in the Open University of Catalonia (UOC). He leads the Office of Learning Technologies. Since 1995 he has worked in the IT department leading the development of the UOC virtual campus platform . His current work focuses on two themes; tools for e-learning platforms... Read More →
avatar for Dr. Geraldine Leader

Dr. Geraldine Leader

Psychologist, behaviour analyst and lecturer in the School of Psychology at the National University of Ireland, Galway
Dr. Geraldine Leader is a psychologist, behaviour analyst and lecturer in the School of Psychology at the National University of Ireland, Galway. Her research interests lie in the area of autism spectrum disorders.  Geraldine is the founding director of the Irish Centre for Autism... Read More →
avatar for Prof. Michael J. Leahy

Prof. Michael J. Leahy

Professor and Director, Office of Rehabilitation and Disability Studies College of Education, Michigan State University,
Michael Leahy is a professor of rehabilitation counseling and director of the Office of Rehabilitation and Disability Studies. His continuing research interests include professional competency development and education, professionalization, regulation of practice, vocational assessment... Read More →
avatar for Jutta Treviranus

Jutta Treviranus

Director, Inclusive Design Research Centre, OCAD University
Jutta Treviranus is the Director of the Inclusive Design Research Centre (IDRC), professor and director of an innovative graduate program in inclusive design at OCAD University Toronto.(http://idrc.ocadu.ca, http://www.ocadu.ca/programs/graduate_studies/inclusive_design.htm). The... Read More →


Thursday March 7, 2013 2:00pm - 4:00pm
Radisson Blu EU Hotel Idaliestraat 35, 1000 Brussels

4:00pm

New Business Models in Personalised Health Care
Limited Capacity seats available

The revolution in healthcare induced by the fast advancing field of personalised medicine influences dramatically the existing business models of pharmaceutical companies and other healthcare industries. The aim of personalised healthcare comprises not only targeted individualised treatment, but also focuses increasingly on effective and efficient prevention strategies. Diagnostics is one of the fields that expand tremendously due to the new function of medical care in the citizen’s life. The healthcare industry must develop now new concepts providing a flexible and sustainable approach to address the new demands of the global market.

Another emerging trend in the healthcare sector is “frugal” or “reverse innovation”.
High-tech healthcare is often costly and cannot be transferred easily to less favoured countries or applied in rural areas. However, poor countries with their only very limited resources can also be drivers for innovation. “Frugal” innovation” is a strategy where innovation is driven by the local or regional demands and according to the availability of the resources. To prepare Europe for the challenges in healthcare and open the ERA for innovative approaches we will discuss this area with experts from countries representing emerging markets.

 

Agenda

 


Moderators
avatar for Angela Brand

Angela Brand

Institute for Public Health Genomics, Maastricht University, The Netherlands
Presentation topic: Personalised Healthcare – what and how to translate?   Prof. Angela Brand, MD PhD MPH (USA) is Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG) at the Faculty of Health, Medicine and Life Sciences at Maastricht University... Read More →
avatar for Babette Regierer

Babette Regierer

Project Developer, LifeGlimmer GmbH

Speakers
avatar for Prof. Frank Bier

Prof. Frank Bier

Fraunhofer Institute for Biomedical Engineering Potsdam, Germany
Presentation topic: New Business Models in Diagnostics for Personalised Heathcare   Professional development | 1977 - 1984 Studies of Physics and Mathematics at University of Münster and Heidelberg University | 1985 - 1989 PhD in Applied Physics at Heidelberg University Guest... Read More →
avatar for Angela Brand

Angela Brand

Institute for Public Health Genomics, Maastricht University, The Netherlands
Presentation topic: Personalised Healthcare – what and how to translate?   Prof. Angela Brand, MD PhD MPH (USA) is Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG) at the Faculty of Health, Medicine and Life Sciences at Maastricht University... Read More →
avatar for Dr. Regina Connolly

Dr. Regina Connolly

Dublin City University, Dublin, Ireland
Dr. Regina Connolly is a Senior Lecturer at Dublin City University, Ireland.  She is editor-in-chief of the Journal of Internet Commerce and program co-chair of the 2013 European Conference of Information Systems. Her research interests include connected health business models, medical... Read More →
avatar for Dr. Giovanni Milandri

Dr. Giovanni Milandri

Technology Project Manager, Medical Research Council’s Medical Device Innovation Platform
Giovanni Milandri is the Technology Project Manager for the Medical Research Council’s Medical Device Innovation Platform. He manages new medical devices in their technical, clinical, legal and business readiness towards being commercialized from SA research institutions, currently... Read More →
avatar for Prof. Kapuetta Satyamoorthy

Prof. Kapuetta Satyamoorthy

Manipal Life Sciences Centre, Manipal University, India
Dr. K. Satyamoorthy obtained his PhD from Bombay University in 1987 and since then, he has been involved in various aspects of research and developmental activities in molecular pharmacology, population variation. | Pharmacogenomcis, human genetics, epigenetics and cancer.  He is... Read More →
avatar for Bonnie Wolff-Boenisch

Bonnie Wolff-Boenisch

Head of Research Affairs, Science Europe
Dr Bonnie Wolff-Boenisch is directing the Division of Research Affairs at Brussels based international organisation “Science Europe”. The newly-founded organisation represents 51 Research Funding and Research Performing Organisations from 26 countries, with an estimated combined... Read More →


Thursday March 7, 2013 4:00pm - 6:00pm
European Parliament J6Q1
 
Friday, March 8
 

9:00am

The Advancement of Medical Devices: Robots in Health Care as a Case Study
Limited Capacity seats available

Medical devices regulation within the EU centers on regulatory framework for market access, international trade relations, and regulatory convergence all with the aim of ensuring patient safety while promoting innovation and competitiveness. The current legal framework has hitherto been criticized for being too fragmented and difficult to follow; however, the medical devices market is truly a global one and alignment on this topic is essential in order to make the medical field as a whole more harmonized and efficient. This is particularly prevalent within Europe as Horizon 2020 emphasizes improved cross-cutting support technologies to facilitate the development of “new, more efficient, effective and sustainable treatments for disease and for the management of disabilities.”

Within the medical devices field, there have been large strides made with respect to the role robots play
in healthcare; yet there is still much debate around the use of robots in healthcare. With this increased role of robots comes the question: “Helping the infirm help themselves: when and where are robots an appropriate health care solution?” If the use of robots in healthcare can be agreed upon to create a
systemized and harmonized model across the union, this will lead to even larger developments in the medical field. 

In this session, the panelists will look at some of the following questions:

  • When should robots be responsible for our healthcare and well-being?
  • How much autonomy should healthcare robots have?
  • How should the user interface look like so that medical professionals can work with the robots?
  • How much should we let robots be responsible for our healthcare?

Moderators
SR

Signe Redfield

U.S. Office of Naval Research Global - London

Speakers
avatar for Catherine Carty

Catherine Carty

UNESCO Chair Project Manager, Institute of Technology Tralee, Ireland, UNESCO Chair
Catherine Carty is the UNESCO Chair Project Manager in the Institute of Technology Tralee, Ireland. The newly established chair is entitled  "Transforming the lives of people with disabilities through Physical Education, Sport, Recreation and Fitness" and it represents a multidisciplinary... Read More →
avatar for Dr. Kerstin Eder

Dr. Kerstin Eder

Reader in Design Automation and Verification, Department of Computer Science, University of Bristol
Dr Kerstin Eder is a Reader in Design Automation and Verification at the University of Bristol.  | She holds a PhD in Computational Logic, an MSc in Artificial Intelligence and an MEng in Informatics. Her research activities are focused on specification, verification and analysis... Read More →
PP

Prof. Paolo Fiorini

IEEE Fellow, Department of Computer Science, University of Verona
DA

Dr. Anders Sandberg

James Martin Research Fellow at the Future of Humanity Institute, Oxford University


Friday March 8, 2013 9:00am - 11:00am
European Parliament J6Q1